B+
Bull case
20%
Probability
Target price
$5.20
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
NKTX
NkartaDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
50%
Probability
Target price
$2.60
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$1.20
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-08
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+54.6
Score
AI commentary
The company IR press-release index checked on August 8, 2026 still showed the May 12, 2026 Q1 release as the latest listed release; no verified Q2 earnings source, analyst revision, target change, or trusted post-print market-reaction explanation was available. The stock was $2.41 on August 7, with no packet social aggregate or recent trusted-news flow. Evidence supports monitoring rather than a high-conviction directional call.
RankAlpha Sentiment Codex - 2026-08-08
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-09-30catalystCash runway remains near-term balance-sheet supportMedium impact
Nkarta reported $266.7 million in cash, cash equivalents, restricted cash, and investments as of March 31, 2026, with funding expected into 2029. This reduces immediate financing pressure, although Q2 cash usage has not been confirmed.[#SEC-8K-2026-05-12]
2026-10-31catalystProtocol amendments may improve trial access and enrollmentHigh impact
FDA-agreed amendments allow outpatient dosing, optional re-dosing, removal of overnight monitoring, and expansion of Ntrust-2 into rheumatoid arthritis. Execution and enrollment progress remain necessary before this becomes a stronger thesis driver.[#SEC-8K-2026-05-12]
2026-12-31eventInitial Ntrust clinical dataset remains the main binaryHigh impact
Initial clinical data from Ntrust-1 and Ntrust-2 are planned for presentation at a medical meeting in 2026. The dataset remains the principal valuation driver, with efficacy and safety still unproven.[#SEC-8K-2026-05-12] [#PR-EARNINGS-2026-05-13]
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-08 • Updated nightlySource: Internal modelMethodology